`
`http://www.bausch.com/our-company/investor-relations#.VkphGivz5Kj
`
`United States
`
`Newsroom Careers Investor Relations
`Contact Us
`
`For Eye Care
`Professionals
`
`Text size A- A+
`
`Our Products
`
`Vision and Age
`
`Your Eye Concerns
`
`Our Company
`
`Home Our Company Investor Relations
`
`Investor Relations
`
`LikeLike
`
`5
`
`Tweet
`
`0
`
`Valeant Pharmaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) completed its acquisition of Bausch + Lomb on August
`5, 2013. Bausch + Lomb will retain its name and become a division of Valeant. Valeant's existing ophthalmology businesses
`will be integrated into the Bausch + Lomb division, creating a global eye health platform with estimated pro forma 2013 net
`revenue of more than $3.5 billion. For Investor Relations information on Valeant, click here.
`
`Vision and Eye Health
`
`Products
`
`Customer Support
`
`Legal
`
`Vision and Age
`Eye Infections & Irritations
`Diseases and Disorders
`Find a Doctor
`Eye Exam Check List
`
`Contact Lenses
`Contact Lens Care
`Dry Eye Products
`Allergy/Redness Relief
`Rx Pharmaceutical
`Eye Vitamins
`Surgical Products
`Vision Accessories
`
`Contact Us
`Customer policies and forms
`Rebate Center
`Worldwide Locations
`
`Legal Notice
`Privacy Policy
`Safety Data Sheets (SDS)
`
`© 2015 Bausch & Lomb Incorporated.
`
`All information and materials on this site pertain to the U.S. only, unless otherwise indicated.
`
`Newsroom
`Careers
`Investor Relations
`Grants & Contributions
`
`1 of 1
`
`11/16/2015 6:05 PM
`
`Page 1 of 1
`
`SENJU EXHIBIT 2184
`LUPIN v. SENJU
`IPR2015-01097